Article
Risk of Adverse Pregnancy Outcomes Associated with Sodium Valproate(VPA): A Disproportionality Analysis Using the FDA Adverse Event Reporting System (FAERS)
2025-05-15
Abstract excerpt
<title>Abstract</title> <p> <bold>Background:</bold> Valproate(VPA) is widely used for treating epilepsy, bipolar disorder, and migraines. However, its use during pregnancy raises concerns due to potential adverse events (AEs) on fetal development. Previous studies have linked VPA to neural tube defects, cardiac malformations, and cognitive impairments in offspring. Despite these risks, some pregnant women cont...
Topics
Open a Topic to create a Post that cites this publication.
Identifiers and source
- Literature Corpus work
- 347048a4-cf45-5fc8-afc7-0721d773da41
- DOI
- 10.21203/rs.3.rs-6482152/v1
